Overview: GAD65 IgG TestIntroduction: The GAD65 IgG Test detects glutamic acid decarboxylase-65 antibodies to diagnose type 1 diabetes or neurological disorders, causing fatigue or tremors. Following 2023 ADA and AAN guidelines, it uses an immunoassay for high sensitivity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected autoimmune conditions.
Other Names: GAD-65 Antibody Assay, Glutamic Acid Decarboxylase Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: GAD65 antibody testing began in the 1990s with type 1 diabetes research. Immunoassays improved in the 2000s, enhancing detection accuracy for autoimmune disorders.
Purpose: Diagnoses type 1 diabetes or neurological disorders, guides treatment, and monitors GAD-65 antibodies in patients with fatigue or tremors.
Test Parameters: 1. Glutamic Acid Decarboxylase-65 IgG
Pretest Condition: Fasting for 10-12 hours required to stabilize antibody levels. Collect serum, CSF, or saliva in the morning. Report symptoms like fatigue or tremors, and list medications.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, tremors, or history of type 1 diabetes/neurological disorders. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for autoimmune therapy.
Procedural Considerations: Uses an immunoassay to detect GAD-65 IgG antibodies. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Non-fasting, hemolysis, or improper storage can affect results. Other autoimmune conditions may cause cross-reactivity.
Clinical Significance: Positive GAD-65 antibodies suggest type 1 diabetes or neurological disorders, prompting treatment. Negative results may require further testing.
Specialist Consultation: Consult an endocrinologist or neurologist for result interpretation.
Additional Supporting Tests: C-peptide, islet cell antibodies, or neurological exams to confirm diagnosis.
Test Limitations: False positives may occur in other autoimmune conditions. Results require clinical correlation.
References: ADA Diabetes Guidelines, 2023; Neurology, Pittock SJ, 2022.
